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Simultaneous lactate production and extraction have been
previously demonstrated in the myocardium in patients
with coronary artery disease. To quantitate this lactate
production and determine its source, dual carbon-la-
beled isotope experiments were performed. L-[1,2,3-13C3)
lactate and D-[6-14C) glucose were infused in 10 patients
with significant coronary artery disease. Metabolic sam-
ples were obtained at rest and during atrial pacing.
Despite net chemical myocardial lactate extraction in
the 10 patients at rest and no evidence of clinical isch-
emia, the L-[l,2,3-13C3] lactate analysis demonstrated
that lactate was being released by the myocardium. Dur-
ing atrial pacing, seven patients did not develop clinical
symptoms of ischemia, and the chemical lactate analysis
showed net lactate extraction. However, tracer analysis
demonstrated that there was a significant increase in the
lactate released during atrial pacing (from 6.9 ± 2.3 to
16.2 ± 10.1 ILmol/min) (p < 0.05). In these seven pa-
The contribution of circulating glucose to lactate production
is poorly defined in the human myocardium. Numerous
studies (1-9) have investigated the source of lactate pro-
duction in the isolated perfused heart or the intact anesthe-
tized dog . Several of these investigations (1-3) suggest that
glycogen stores arean important source of the lactate produced
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tients, circulating glucose was the source of 23 ± 15%
of the lactate released at rest, and there was no signif-
icant change during pacing. The remaining three pa-
tients had mild chest pain and net chemical lactate
production during pacing. Lactate release detected by
the tracer increased from 5.7 ± 3.0 ILmol/min at rest
to 50.9 ± 16.8 ILmol/min during pacing (p < 0.01).
In these patients, the contribution of glucose to lactate
production increased significantly during pacing-
induced clinical ischemia from 25 ± 22 to 67 ± 14%
(p < 0.005).
Thus, dual carbon-labeled isotopic experiments are
powerful tools for investigating myocardial metabolic
pathways. This technique permits the quantitation of the
amount of lactate being released by the myocardium and
the contribution of circulating glucose to the lactate re-
leased during various interventions in human patients.
(J Am Coli CardioI1985;5:1138-46)
during ischemia or hypoxia. Other studies (5-7,9) indicate
that circulating exogenous glucose is the major source of
the lactate .
Using arterial-coronary sinus differences to investigate
human myocardial glucose metabolism, several investiga-
tors have reported conflicting results concerning the source
of lactate production. Kaijser et al. ( 10) did not observe an
increase in glucose extraction during pacing-induced myo-
cardial lactate production . and they hypothesized that gly-
cogen was the source of the lactate. Most et al. (11) reported
that glucose extraction increased during myocardial lactate
production in patients with coronary artery disease; their
data suggest that circulating exogenous glucose is the source
of myocardial lactate production .
Using a tracer technique. we previously demonstrated
(12) that the myocardium releases a significant amount of
lactate in patients with coronary disease at a time when the
chemical arterial-coronary sinus difference shows net myo-
cardial lactate extraction. During this study, these patients
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did not have any evidence of clinical ischemia. To quantitate
myocardial lactate release and determine its source, we per-
formed dual carbon-labeled isotope experiments using L-
[I,2,3- '3C3J lactate and D-[6- '4C] glucose in patients with
chronic ischemic heart disease. The dual carbon-labeled
isotope approach is a unique method for the investigation
of myocardial metabolism. To our knowledge, no previous
reports describing this technique in human subjects have
appeared.
Methods
Patient selection. The study group consisted of 13 men,
aged 49 to 72 years, who underwent clinically indicated
selective coronary angiography for chest pain. The protocol
was approved by the Committee on Human Research of the
University of California at San Francisco and the Human
Research Committee at the San Francisco Veterans Admin-
istration Medical Center. The use of radioisotopes was ap-
proved by the Radiation Safety Committee of the Veterans
Administration Medical Center. Each subject was informed
of the nature, purpose and possible risks involved in the
study before written consent was obtained.
None of the patients included in this study was diabetic
or had a history of glucose intolerance. Three of the 13
patients were taking only nitroglycerin for episodes of chest
pain. The remaining 10 patients were receiving long-acting
nitrates, and 8 of these were taking a beta-adrenergic an-
tagonist. There was no alteration in drug therapy or dosage
before this study. No patient had any chest pain in the 24
hours preceding this study. Each patient underwent left ven-
triculography and selective coronary angiography; however,
the metabolic pacing study always preceded angiography.
Protocol. The patients were fasting for 12 hours before
the study. An anteromedial antecubital vein was exposed
using local lidocaine anesthesia; a 7F Wilson-Webster ther-
modilution-flow pacing coronary sinus catheter was inserted
into the vein and positioned under fluoroscopic guidance in
the mid region of the coronary sinus. The pressure and
oxygen content were measured to verify that the catheter
was in the coronary sinus; no contrast agent was injected
(13). To avoid reflux in the coronary sinus (14), the sam-
pling orifice of the catheter was at least 30 mm from the
ostium of the coronary sinus. The catheter position was
confirmed retrospectively from the cineangiograms by ob-
serving the venous filling phase of the coronary sinus after
an intraarterial injection of the left coronary artery. In ad-
dition, no patient included in the study had evidence of right
heart failure or a mean right atrial pressure greater than 5
mm Hg. The stability of the catheter position was verified
by comparison of video disc images recorded at the begin-
ning and the end of the metabolic procedure.
For arterial blood samples, a short polyethylene sheath
was inserted into the femoral artery by the Seldinger tech-
nique. All patients received heparin (10,000 units) as an
intravenous bolus before the arterial puncture.
L-fJ ,2 ,3_13C1/ lactic acid (56% triple-labeled 13C) was
obtained from Los Alamos Scientific Laboratory as L-[I ,2,3-
13e11 zinc lactate. This was converted to L-[ I ,2,3- 13C31
lactic acid (triple-labeled '3Crlactate) by dissolving the zinc
lactate in distilled water and passing the solution through a
cation exchange column (15). The resulting solution of tri-
ple-labeled '3Crlactic acid was neutralized with 1.0 M so-
dium hydroxide and then sterilized by passing it through a
0.22 J.L Millipore bacteriologic filter. To ensure that the
preparation was pyrogen-free, the Limulus lysate test was
performed (16). D-[6- 14C] glucose was obtained from New
England Nuclear Corporation (specific activity 56.1
mCi/mmol) and sterilized in the same manner.
To achieve a steady arterial level of triple-labeled 13Cr
lactate of 1.5 to 2.0% of the circulating chemical lactate, a
priming dose of 110 mg of 13Crlactate infused over 2 min-
utes was required. This was followed immediately by an
intravenous infusion of the stable isotope at a constant rate
of 130 mg/hr. After a priming bolus of 16 J.LCi, D-[6- '4C]
glucose was infused intravenously at a constant rate of 10
J.LCi/hour. The patients received simultaneous infusions of
D-[6- '4C] glucose and triple-labeled '3Crlactate.
Arterial and coronary sinus blood samples were obtained
simultaneously for '3Crlactate analysis, the specific activity
of glucose and secondarily-labeled lactic acid C4C-analysis)
and the determination of the chemical concentrations of
lactate and glucose. To ensure equilibration of the tracers,
all samples were obtained at least 25 minutes after the ini-
tiation of the dual isotope infusion. At rest, two paired
arterial and coronary sinus blood samples were obtained 10
minutes apart in all patients. Coronary sinus pacing was
performed at a rate of 30 beats/min faster than the rest heart
rate; after 10 minutes of pacing, simultaneous arterial and
coronary sinus samples were obtained for the analyses just
described. Coronary sinus blood flow was measured by a
thermodilution technique (17).
Previously, we have used L-II- 14C] lactate as a tracer
and have demonstrated that the amount of lactate undergoing
oxidative decarboxylation by the myocardium is highly cor-
related with the myocardial uptake determined by the tracer
(12). We have also compared the myocardial isotope ex-
traction ratios obtained using the triple-labeled 13Crlactate
with those of [1_'4CI lactate in three patients (15). The
results of the radioisotopic and stable isotopic analyses were
very similar, with a correlation coefficient of 0.96 for 10
samples in these subjects (SEE y on x = 5.0%) (15).
Chemical analysis. Blood samples for lactate and glu-
cose were mixed immediately with a measured volume of
cold 7% perchloric acid and centrifuged; the protein-free
supernatant was stored at - 4°C for future analysis. Lactate
concentration was determined in the protein-free fluid by an
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enzymatic spectrophotometric method (18). For this method,
the coefficient of variation of 50 analyses of one blood
sample in our laboratory was 1.6%. Glucose was measured
in the protein-free fluid by a hexokinase/glucose-6-phos-
phate dehydrogenase-coupled enzymatic method, with a
coefficient of variation of 1.5% (19).
L-{1.2.3- 13C3J lactate analysis was performed using gas
chromatography/mass spectrometry (15). The protein-free
fluid was neutralized with potassium carbonate and passed
successively through a cation exchange column, H+ form
(AG 50W-X8) and an anion exchange column, CI- form
(AG I-X8). The effluent was lyophilized and the lactic acid
was converted to the methyl ester using BCl3/methanol. The
excess BCl3/methanol was carefully evaporated to dryness
with a stream of N2 to avoid loss of the methyl ester. The
dry residue was then extracted with methylene chloride.
With the addition of BSTFA (Supelco, Inc.), the methyl
ester was converted to the trimethylsilyl ether. The con-
centration of triple-labeled trimethylsilyl ether of 13C-methyl
lactate was determined using an Infratronics model 2400
gas chromatograph interfaced to a Kratos MS-12 mass spec-
trometer. The gas chromatograph used a 4 m x 2 mm glass
U tube column packed with 10% SP-2250 on 100/120 Su-
pelcoport (Supelco, Inc.) at 125°C isothermal and helium
flow rate of 25 mllmin. The mass spectrometric operating
conditions were as follows: ion source temperature: 180°C;
nominal base accelerating voltage: 8 kV; trap current: 500
/-LA; electron energy: 50 eV; resolving power: 1,200. For
the determination of percent of L-[I,2,3- L~C3] lactate, the
ion currents were recorded at m/e 161 and at m/e 164.
Standards containing 0.0,0.5,0.75, 1.0, 1.5 and 2.0%
triple-labeled '3Crlactic acid were prepared by dilution with
unlabeled lactic acid. The standards were treated in the same
fashion as the column effluents just described. A standard
curve was obtained on the gas chromatograph/mass spec-
trometer for each set of assays. Twelve analyses of a pooled
blood sample containing 1.44% triple-labeled 13Crlactate
yielded a coefficient of variation of 3.7% for this method.
Glucose. lactate and pyruvate were separated by ion
exchange chromatography as previously described (12). The
protein-free fluid was neutralized and passed successively
through cation and anion exchange columns to remove la-
beled ionic compounds. Portions of the eluates containing
glucose in water, lactate in 0.25 M sodium acetate and
pyruvate in 0.25 M sodium acetate, respectively, were as-
sayed by the described enzymatic methods. Other portions
were mixed with Aquasol, and 14C was measured in a scin-
tillation counter. Results of scintillation counting are ex-
pressed as disintegrations per minute (dpm) and the specific
activity is calculated as dpm/urnol. The coefficient of vari-
ation for specific activity of lactate was 2.5% in our labo-
ratory (six analyses of one sample). All isotopic and chem-
ical analyses were performed in duplicate.
Calculations. The chemical extraction ratio was cal-
culated from the arterial and coronary sinus lactate concen-
trations as:
0...[A....:...I----'['-C---'SI x 100.[A]
where [A] = arterial lactate concentration and rCS] =
coronary sinus concentration.
The isotope or L-{1,2 .3_13C3Jlactate extraction ratio was
calculated from the concentration of triple-labeled 13Crlac-
tate in the artery and coronary sinus as:
[AI x % DC, in artery - [CS) x % DC, in coronary sinus
11 x 100.[A] x % -C, in artery
13C -lactate
where % 13C3 = 3 X 100 (% 13C3 is obtained
- chemical lactate -
directly from gas chromatography/mass spectrometry).
Myocardial lactate uptake expressed as /-Lmollml of blood
was determined by the isotope technique as:
L-[ 1.2.3- I'C,] lactate extraction ratio
[A] x . 100
The amount of lactate (umol] released or produced by
the myocardium per minute was calculated as:
L-[I,2,3- 13C,J lactate uptake - ([A] - [CS)) x flow.
The contribution of circulating exogenous glucose to the
lactate released or produced by the myocardium was cal-
culated from the observed and theoretical disintegrations
per minute (dpm) of lactate/ml of blood in the coronary
sinus and the specific activity of arterial glucose (dpm/urnol)
as:
(Observed - theoretical) dpm lactate/ml in the coronary sinus X 2*
Specific activity of arterial glucose
x Flow.
*Note factor of 2 used because one molecule of glucose
yields two molecules of lactate.
The actual or observed disintegrations per minute of
lactate per milliliter of blood in the coronary sinus was
calculated from the chemical concentration of lactate in the
coronary sinus (umol/ml) and the specific activity of lactate
in the coronary sinus (dpm/umol) as:
[CS] x Specific activity of coronary sinus lactate.
Since the isotope lactate uptake reflects the actual uptake
of this substrate, the theoretical disintegrations per minute
due to lactate was determined using the isotope uptake and
the specific activity of arterial lactate (dpm/urnol), that is,
the specific activity of lactate would be the same in the
artery and coronary sinus if the myocardium was not re-
leasing lactate. Thus, the theoretical disintegrations per min-
ute due to lactate per milliliter of blood was determined as:
(IAI - L-[ 1,2,3-"C,llactate uptake in ILmol/ml) x Specific activity
of arterial lactate.
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Statistics. The statistical significance of the changes in
lactate released, arterial substrate levels and arterial-coro-
nary sinus differences for various substrates was determined
by two-way analysis of variance and the Newman-Keuls
test. The unpaired t test was used to compare the amount
of lactate released between the two groups of patients. All
results are expressed as mean ± standard deviation.
Results
Patient subgroups. Ten of the 13 patients receiving si-
multaneous infusions of D-[6_14C] glucose and triple-labeled
13Crlactate had significant coronary artery disease as doc-
umented by coronary angiography. A significant lesion was
defined as that compromising the luminal diameter by 50%
or greater. The three patients (aged 51, 53 and 61 years)
without any significant coronary lesions underwent selective
coronary angiography for chest pain.
The JO patients with significant coronary disease were
divided into two groups depending on the absence or pres-
ence of clinical symptoms of ischemia during the submax-
imal atrial pacing period. Seven of the 10 patients did not
develop any clinical symptoms or electrocardiographic
changes, while the remaining 3 patients experienced mild
chest pain during atrial pacing. One of latter three patients
also developed premature ventricular beats during this period.
In the seven patients without pacing-induced clinical
ischemia, four patients had significant three vessel disease,
and only one of these four patients had a 50% left main
coronary artery lesion. Two of the remaining patients had
significant two vessel disease and one had only a significant
proximal coronary lesion in the left circumflex vessel. In
comparison, all three of the patients who developed mild
chest pain with pacing had severe three vessel disease; all
vessels had proximal 85% or greater stenosis, and two of
Figure I. Arterial (ART)and coronarysinus (CS)specific activity
of glucose plotted against time in an individual receiving 0-[6-
14C] glucose as a tracer. The priming dose was given and the
constant intravenous infusion was begun at time O. OPM = dis-
integrations per minute.
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the three patients had a 85 to 95% left main coronary artery
lesion.
Isotope equilibration and steady state. Figure I shows
the arterial and coronary sinus specific activity of glucose
in an individual patient. The intravenous infusion of 0-[6-
14C] glucose was started immediately after the priming dose
at time O. Using this infusion technique, the arterial and
coronary sinus specific activity reach a plateau after 20
minutes of infusion. As previously published (12), 15 to 20
minutes was also required for the lactate tracer to achieve
a steady state. Thus, to ensure equilibration of the dual
tracers, all samples for chemical or isotopic analyses were
obtained at least 25 minutes after the initiation of the dual
isotope infusion.
In the rest state, two samples were obtained 10 minutes
apart for both chemical and isotopic analyses to ensure sta-
bility of substrate levels. The arterial level of glucose was
5.52 ± 0.52 p,mollml and the specific activity of arterial
glucose was 443 ± 73 dpm/umol. There was no significant
difference in the chemical concentration or the specific ac-
tivity of this substrate between the two rest samples.
The arterial level oflactate measured chemically in these
subjects was 0.617 ± 0.216p,mol/ml. The percent of triple-
labeled 13Crlactate in the arterial blood was 1.58 ± 0.34%
after the 25 minute equilibration period. Likewise, there
was no significant change in the arterial level of lactate or
the percent of the stable lactate isotope between the two rest
points.
Lactate extraction and release at rest. In the 10 pa-
tients with significant coronary artery disease, the myo-
cardial chemical lactate extraction ratio was 16 ± 9% at
rest, with a range from 4 to 32%. The L-[ I ,2,3- IJC3) lactate
extraction ratio for these patients was 29 ± 12%, with a
range from 13 to 50%. In these patients at rest, there was
a significant difference between the lactate extraction ratios
determined by chemical analysis and the stable isotope (p <
0.001). In the three patients without significant coronary
disease, the chemical lactate extraction ratio was 31 ± 7%
and the isotope ratio was 45 ± 4% at rest.
In all patients the isotope lactate extraction ratio deter-
mined by the triple-labeled '3Crlactate tracer was greater
than the chemical extraction ratio. If certain areas of the
myocardium are releasing or producing lactate, unlabeled
lactate (nontriple-Iabeled 13Crlactate) would appear in the
venous or coronary sinus effluent. This unlabeled lactate is
measured by the chemical enzymatic method and the chem-
ical concentration in the coronary sinus is elevated and does
not reflect the "true" or actual extraction of the substrate
by the myocardium. Thus, the traditional arterial-coronary
sinus chemical extraction ratio for lactate underestimates
the actual myocardial uptake of this substrate and is lower
than the isotope extraction ratio. The difference between
the isotope and chemical extraction ratios represents the
amount of myocardial lactate release.
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The myocardial lactate uptake can be calculated from
the L-(I ,2,3- IJ C31 Iactate tracer by multiplying the arterial
lactate concentration by the isotope extraction ratio. The
difference between the isotope uptake and the chemical ar-
terial-coronary sinus concentration is the amount of lactate
released. The amount of lactate released was 0.076 ± 0.029
JLmollml of blood in the 13 patients at rest. The coronary
flowdetermined by coronary sinus thermodilution technique
was 92 ± 42 ml/min; the amount of lactate released or
produced was 6.6 ± 2.1 JLmollmin at rest. There was no
significant difference in the amount of lactate released be-
tween the two sampling points at rest. These observations
are consistent with our previous data (12) which showed
that there is myocardial release or production of lactate at
rest in patients with coronary artery disease.
Atrial pacing. At rest. the mean heart rate was 67 ±
13 beats/min. Coronary sinus pacing was performed at 30
beats/min above the rest state. During the pacing stress test,
there was no significant change in the arterial substrate lev-
els. The arterial glucose level during pacing was 5.51 ±
0.59 JLmol/ml compared with 5.52 ± 0.52 JLmollml at rest
(p = NS); likewise the arterial lactate was 0.631 ± 0.233
and 0.617 ± 0.216 JLmollml, respectively (p = NS).
During pacing. 7 of the 10 patients with significantcoro-
nary artery disease had no symptomsor electrocardiographic
signs of ischemia. The remaining three patients had clinical
evidence of ischemia during this period; all three had mild
chest discomfort and one developed premature ventricular
beats with atrial pacing.
In the seven patients without clinically evident pacing-
induced ischemia. chemical analysis showed net myocardial
lactate extraction during pacing. However, the tracer method
demonstrated that lactate released per milliliter of blood
increased significantly in these patients during the pacing
(from 0.084 ± 0.026 JLmol/ml at rest to 0.123 ± 0.042
JLmol/ml with pacing) (p < 0.025). The percent of L-[1,2,3-
13C3] lactate in the artery and the coronary sinus in one of
these seven patients is shown in Figure 2 for the two rest
points and during the 10 minute pacing period. The percent
of triple-labeled 13Crlactate is lower in the coronary sinus
compared with the artery because unlabeled (nontriple-la-
beled 13Crlactate) is released by the myocardium. During
the rest period, the percent of stable isotope remained con-
stant, and with pacing the arterial level was virtually un-
changed. In the example in Figure 2, the arterial percent of
triple-labeled 13Crlactate was 1.89% at rest and 1.92% dur-
ing pacing. With pacing, however, there was a marked
decrease in the percent of triple-labeled '3Crlactate in the
coronary sinus (1.55% at rest compared with 1.35% during
pacing). This decrease in the percent of triple-labeled 13Cr
lactate indicates that more unlabeled lactate is being released
or produced by the myocardium during the stress of atrial
pacing as compared with at rest.
Coronary flow increased in five of the seven patients
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Figure 2. Patient 5. The percent of triple-labeled 13Crlactate in
the artery (ART) and coronary sinus (CS) over the time course of
the experimentin one of the seven patientswithoutpacing-induced
ischemia. The priming dose of [I ,2.3-13C .J! lactate was given at
time 0 and the constant intravenous infusion of the stable isotope
was started. With atrial pacing (arrow), there is a decrease in the
percent of triple-labeled 13Crlactate in the coronary sinus, which
indicates there is an increase in the amount of unlabeled lactate
being released from the myocardium .
during atrial pacing . Using the coronary flow data, the
amount of lactate released at rest was 6.9 ± 2.3 JLmollmin
in these seven patients without clinical symptoms and the
amount released increased significantly to 16.2 ± 10.1
JLmol/min during pacing (p < 0.05) (Table I).
In the three patients who developed chest pain during
atrial pacing. there was net myocardial lactate extraction
at rest; however, with pacing net chemical lactate production
occurred. The L-[I,2,3 -13C3] lactate analysis showed that
per milliliter of blood, 0.041 ± 0.018 JLmol of lactate was
released at rest and this increased to 0.214 ± 0.044 JLmol
with pacing in these three patients. Taking coronary flow
into account, the total lactate released was 5.7 ± 3.0
JLmol/min at rest and 50.9 ± 16.8 JLmollmin during pacing
(p < 0.0 I) (Table 2).
In the three patients without significant coronary artery
stenosis , tracer analysis showed that myocardial lactate re-
lease occurred at rest. However, in contrast to the findings
in the patients with significant lesions, there was no increase
in myocardial lactate release during submaximal atrial pac-
ing. The amount of lactate released per milliliter of blood
was 0.093 ± 0.004 JLmol at rest and 0.078 ± 0.006 JLmol
at 10 minutes of atrial pacing; the total lactate released
was 6.9 ± 0.6 and 6.6 ± 2.0 JLmol /min, respectively
(p = NS).
Contribution of circulating glucose. The arterial and
coronary sinus-specific activities of lactate are shown for an
individual patient in Figure 3. When 16-14C) glucose was
infused, secondary labeling of lactate occurred. Thus, the
arterial lactate was labeled with (olC and the amount of
arterial 14C-Iactate increased throughout the duration of the
study. However, the specific activity of lactate was higher
in the coronary sinus as compared with the artery. This
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Table I. Seven Patients Without Clinical Symptoms During Atrial Pacing Stress
Exogenous Glucose Converted Lactate Released
Lactate Released 10 Lactate and Released From Exogenous Glucose
Case (~mol/min) (~mol!min) (%)
Rest
I 5.3 1.7 32
2 10.3 3.8 37
3 7.8 3.0 38
4 4.7 0 0
5 6.3 1.9 30
6 9.2 0.7 8
7 4.6 0.8 17
Atrial pacing
I 11.2 .H 34
2 14.3 2.6 18
3 10.6 3.2 30
4 372 6.6 18
5 14.2 5.4 38
6 19.8 3.2 16
7 6.4 U 20
Mean ± SD
Rest 6.9 "!: 2.3 1.7 ± 1.3 23 ± 15
Atrial pacing 16.2 ± 10.1* 3.7 .:t 1.8t 25 ± 9
*p < 0.05 for values at rest versus pacing: tno significanl difference for values at rest versus pacing.
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finding indicates that circulating glucose was converted to
lactate and that the lactate was released by the myocardium.
Having determined the L-[ 1.2,3- I1C31 Iactate uptake and
the specific activity of glucose and lactate in the artery and
coronary sinus. we calculated the contribution of circulating
glucose to lactate release. At rest in the 10 patients with
significant coronary artery disease. the source of 24 ± 16%
ofthe lactate released wasfrom circulating exogenous glucose.
Patients without chest pain during pacing. The contri-
bution of circulating exogenous glucose to the lactate re-
leased in the seven patients who did not develop chest pain
during pacing is shown in Table I. At rest. 23 ± 15% of
the lactate released was from circulating glucose. The amount
of circulating glucose converted to lactate and released was
I .7 ± 1.3 jLmollmin at rest and 3.7 ± 1.8 jLmollmin during
pacing; however. this change was not significant and there
was no significant difference in the relative contribution of
circulating glucose to lactate (23 ± 15 and 25 ± 9%.
respectively). The remainder (70 to 80%) of the lactate
released probably came from glycogen. although we have
no data to directly substantiate this hypothesis.
Patients with pacing-induced ischemia. The amount of
lactate released and the contribution of circulating exoge-
nous glucose to this lactate release in the three patients with
pacing-induced clinical ischemia is shown in Table 2. Dur-
ing pacing, there was a significant increase in the amount
of lactate released (p < 0.0 I). The amount of lactate derived
from circulating glucose was 1.9 ± 1.8 jLmQI/min a) rest
Table 2. Three Patients With Mild Chest Pain During Atrial Pacing Stress
Exogenous Glucose Converted Lactate Released
Lactate Released to Lactate and Released From Exogenous Glucose
Case (~mol!min) (~mol!min) (%)
Rest
8 6.2 2.0 32
9 8.4 3.6 43
10 2.5 0 0
Atrial pacing
8 59.9 34.7 58
9 61.2 36.5 60
10 31.5 26.3 83
Mean ± SD
Resl 5.7 ± 3.0 1.9 ± 1.8 25 ± 22
Atrial pacing 50.9 ± 16.8* 32.5 ± 5.4t 67 ± 14
*p < 0.01 for values at rest versus pacing; tp < 0.005 for values at rest versus pacing.
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or signs of clinical ischemia. Using triple-labeled 13Cr
lactate, we found similar results and, in addition, demon-
strated in three subjects that the results are identical when
the stable isotope L-[ I ,2,3- 13C3J lactate is compared with
the radioisotope [1_'4C] lactate (15).
Silent ischemia. The concept of silent ischemia in pa-
tients with coronary artery disease and angina has been
raised; that is, does myocardial ischemia exist at rest or
during submaximal work loads in the absence of chest pain
or other cardiac symptoms? Using Holter monitoring, in-
vestigators (23,24) have found electrocardiographic evi-
dence of ischemia (ST segment depression) at work loads
below those associated with angina on a treadmill test. Dur-
ing these recordings, the patients did not have any chest
discomfort, shortness of breath or any other clinical man-
ifestation of ischemia.
In our study, coronary sinus pacing was used as a means
of stressing the myocardium. Coronary sinus pacing was
performed at a rate of 30 beats/min higher than the heart
rate at rest. In all 13 patients included in our study, this
heart rate was lower than the heart rate associated with chest
pain on an exercise treadmill test (Bruce protocol). When
atrial or coronary sinus pacing is used as a stress test, symp-
toms usually develop at a rate 10 beats/min higher than the
heart rate achieved on an exercise treadmill test (10,25).
Seven of the 10 patients with significant coronary artery
disease did not develop cardiac symptoms during submax-
imal pacing. Chemical lactate analysis demonstrated net
myocardial lactate extraction in each of these patients during
pacing. However, there was a significant increase in myo-
cardial lactate release as detected by the isotope during the
submaximal atrial pacing test in these seven patients (p <
0.05) (Table I). In the three patients without significant
coronary artery disease, there was no increase in myocardial
lactate release during atrial pacing. The data in these patients
support the concept of silent ischemia in patients with coro-
nary artery disease.
Myocardial biochemical alterations during submaximal
and maximal stress. The myocardial biochemical altera-
tions that occur with chest pain are not "all or none phe-
nomena," but rather a continuous process (26). The bio-
chemical alterations of ischemia begin to occur gradually
in response to submaximal stress without clinical manifes-
tations and increase in severity until overt clinical symptoms
of angina occur (27). Using radionuclide techniques, Hecht
et al. (28) evaluated ejection fraction and the development
of regional wall motion abnormalities during submaximal
and maximal atrial pacing in patients with coronary artery
disease. During submaximal pacing, there was a significant
decline in ejection fraction compared with that at rest, and
5 of their 12 patients developed new regional wall motion
abnormalities. During maximal pacing, a further decline in
ejection fraction occurred with the development of four new
regional wall motion abnormalities and worsening of several
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Figure 3. Patient 5. Lactate is labeled secondarily when 14C_
glucose is infused. The arterial and coronary sinus-specific activity
of lactate (dprn/urnol) plotted against time. At time 0, the priming
dose of D-[6-14C] glucose was given and the constant infusion of
the tracer was begun. The specific activity of the lactate is higher
in the coronary sinus compared with the artery becauseexogenous
[6_ 14C] glucose is extracted and converted to 14C lactate by the
myocardium. Abbreviations as in Figure 2.
Discussion
Underperfused myocardial areas in coronary artery
disease. In patients with significant coronary artery disease,
underperfused regions of the myocardium have been dem-
onstrated at rest. Klocke (20) and Cannon (21) and their
colleagues have documented a decrease in regional myo-
cardial blood flow in these patients. Gewirtz et al. (22)
reported transient defects in thallium-20 I myocardial scin-
tigrams at rest in patients with severe coronary lesions. A
decrease in regional blood flow may result in localized isch-
emia and production of lactate while other regions of the
myocardium are extracting this substrate.
Using the radioisotope [1_14C] lactate as a tracer, we
previously demonstrated (12) that lactate is released or
produced by the myocardium in patients with coronary dis-
ease at a time when there is net myocardial chemical lactate
extraction. This occurs at rest in the absence of symptoms
and this increased to 32.5 ± 5.4 JLmollmin during pacing
(p < 0.005). This was significantly different (p < 0.001)
from the contribution of circulating exogenous glucose to
the lactate released in the seven patients without cardiac
symptoms during pacing.
The mean arterial glucose level in these 10 fasting pa-
tients was 5.58 ± 0.54 JLmol/ml. At rest, the arterial-coro-
nary sinus glucose difference was 0.10 ± 0.10 JLmollml,
and there was no significant change during pacing in the
seven patients without cardiac symptoms (0.13 ± 0.10
JLmollml). Likewise in the three patients with pacing-in-
duced chest pain, there was no significant difference in the
arterial-coronary sinus glucose difference during pacing
compared with rest (0.10 ± 0.02 and 0.12 ± 0.04 JLmollml,
respectively).
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existing wall motion abnormalities, These investigators also
measured chemical myocardial lactate extraction. They found
a graded decrease in the chemical lactate extraction during
the submaximal and maximal pacing periods, with eight
patients developing net myocardial chemical lactate pro-
duction during maximal pacing. In our present study. by
using tracer techniques we demonstrated that an increase in
myocardial lactate release occurs during submaximal stress
in patients with significant coronary artery disease in the
absence of cardiac symptoms.
Dual carbon-labeled experiments. In this study, triple-
labeled 1.1C..-lactate was used as a tracer to quantitate the
"true" or actual lactate extracted by the myocardium, and
the amount of lactate released. [6_14C) glucose was infused
to determine the contribution of exogenous glucose to this
released lactate. When '4C-glucose is infused. other sub-
strates such as lactate are labeled secondarily. Knowing the
"true" or actual myocardial lactate extraction determined
by the L-[ I ,2,3- IJ C1] lactate enables us to calculate the
theoretical disintegrations per minute of lactate per milliliter
of blood in the coronary sinus. Lactate is separated from
all other labeled substrates with ion exchange chromatog-
raphy and the actual disintegrations per minute of lactate
per milliliter of blood is determined. From the theoretical
and actual or observed values of disintegrations per minute
of the labeled lactate per milliliter of blood and the specific
activity of arterial glucose, the amount of exogenous glucose
converted to lactate can be calculated.
Using dual carbon-labeled experiments in this study, we
have demonstrated that 20 to 30% of the lactate released
comes from circulating glucose; the remainder (70 to 80%)
probably comes from other sources, most likely glycogen.
This applies to the fasting, resting state. During submaximal
atrial pacing, that is. a pacing rate that does not produce
chest pain, there was an increase in the lactate released.
Despite this increase, the relative contribution of exogenous
glucose to the lactate released was similar to that at rest in
seven of our patients. However. during pacing-induced chest
pain in three patients, we have shown that the contribution
of circulating exogenous glucose to the lactate released in-
creased significantly.
Contribution of circulating glucose to lactate produc-
tion. Various investigators (1-3) have stressed the impor-
tance of glycogen stores as the source of lactate during
ischemia or hypoxia. Using isolated perfused hearts. they
found that glycogen depletion is associated with lactate pro-
duction during ischemia or hypoxia. Other animal studies
(5-7,9) have demonstrated that the myocardium uses cir-
culating glucose for lactate production during ischemia or
hypoxia. Several investigators have attempted to assess the
role of circulating glucose during myocardial ischemia in
human patients. Kaijser et al. (10) measured chemical lac-
tate and glucose concentration in the artery and coronary
sinus. During pacing-induced myocardial ischemia that re-
suited in net chemical lactate production, they did not find
an increase in myocardial glucose extraction. Therefore,
they assumed that glycogen was the source of the lactate
produced. The chemical myocardial glucose extraction data
in our study agree with their findings. However, by using
labeled substrates, we were able to detect an increase in the
contribution of circulating exogenous glucose to lactate pro-
duction during pacing-induced chest pain. Thus, despite the
absence of a significant change in the arterial-coronary sinus
difference for glucose, there was a significant increase in
the utilization of exogenous glucose for lactate production
during pacing-induced ischemia. Studies in isolated heart
preparations (6) have shown that there are several metabolic
pathways for exogenous glucose: oxidation, glycogen stor-
age. utilization by the hexose monophosphate shunt pathway
and lactate production. Using a similar animal model, it has
been demonstrated (29) that hypoxia or ischemia activates
the glycolytic pathway which results in lactate production.
Our results suggest that in human subjects during pacing-
induced ischemia, the intramyocardial pathways of exoge-
nous glucose are probably shunted from oxidation and gly-
cogen storage to lactate production.
Conclusions. This study supports the concept that the
biochemical alterations of ischemia can occur at submaximal
stress without the clinical manifestations of ischemia, that
is. silent ischemia. It also demonstrates for the first time in
human subjects the utility of dual carbon-labeled isotopes
to investigate myocardial metabolism. The use of triple-
labeled 1.1C.rlactate as a tracer enabled us to measure the
"true" myocardial lactate uptake and calculate the amount
of lactate released by the myocardium. The contribution of
circulating exogenous glucose to the lactate released was
determined by using the '4C-glucose tracer. The dual car-
bon-label approach appears to be a very promising and pow-
erful tool for investigating metabolic pathways in the human
myocardium, both in normal subjects and in those with
various disease states. The knowledge gained with this tech-
nique may enable the evaluation of new therapeutic ap-
proaches directed toward the improvement of myocardial
function.
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